Pure Global
NCT05847088

Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema:

Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema: Anatomical and Functional Outcomes of Treatment and Retreatment
Dar El Oyoun Hospital·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetic Macular Edema
Drug/Device/Intervention
Intravitreal Dexamethasone Implant for refractory Diabetic macular edema:
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Dar El Oyoun Hospital
Location
Cairo, Egypt
Timeline & enrollment
Phase
N/A
Start date
Feb 15, 2023
End date
Apr 04, 2023
Enrollment
58 participants
Primary outcome

Change in Central macular thickness (in microns) (CMT change ),Change in Best corrected visual acuity (BCVA change) )

Summary

We have been using DEX for refractory DME for a long time (since 2016). Thus, we are sharing
 our results , evaluating both anatomical and functional outcomes of DEX therapy for
 refractory DME.

ICD-10 classifications
Diabetic retinopathyOther specified diabetes mellitus with ophthalmic complicationsUnspecified diabetes mellitus with ophthalmic complicationsDiabetic cataractType 2 diabetes mellitus with ophthalmic complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05847088
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05847088 through Pure Global AI's free database. This phase not specified trial is sponsored by Dar El Oyoun Hospital and is currently Completed. The study focuses on Diabetic Macular Edema. Target enrollment is 58 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.